SGHT (Sight Sciences) GF Value Rank: 7 (As of Jul. 15, 2026) — 75% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGHT Sight Sciences Inc SGHT
73 GF Score
Price $5.25
GF Value $4.51
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Sight Sciences GF Value Rank?

Sight Sciences SGHT +3.96% 73 GF Value Rank is 7 as of Jul. 15, 2026, which is 75% above its 10-year median of 4.00. GuruFocus rates SGHT with a GF Score™ of 73/100 and a GF Value™ of $4.51 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Sight Sciences has the GF Value Rank of 7.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Sight Sciences GF Value Rank Related Terms


SGHT vs SENS, LAB, TMCI: GF Value Rank Comparison

For the Medical Devices subindustry, Sight Sciences's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sight Sciences GF Value Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Sight Sciences's GF Value Rank falls into.


SGHT
73GF Score
Sight Sciences Inc SGHT
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 7 mean?
Sight Sciences (SGHT) has a GF Value Rank of 7 as of Jul. 15, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Sight Sciences and its competitors. This is 75% above median its historical median of 4.00. Over the past decade, Sight Sciences' GF Value Rank has ranged from 1.00 to 10.00.
Is Sight Sciences' GF Value Rank too high?
Sight Sciences' current GF Value Rank of 7 is 75% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Sight Sciences has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' GF Value Rank compare to SENS and LAB?
Sight Sciences' GF Value Rank of 7 can be compared against companies in the Medical Devices & Instruments industry. Historically, Sight Sciences' own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Medical Devices & Instruments company?
A good GF Value Rank depends on the Medical Devices & Instruments industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Sight Sciences and its competitors. Sight Sciences's current GF Value Rank is 7, which is 75% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.51, compared to a current price of $5.25 — trading 16.4% above its estimated fair value. The current GF Value Rank is 7, which is 75% above median its 10-year median of 4.00. Sight Sciences' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Sight Sciences (SGHT), the current GF Value Rank is 7 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sight Sciences (SGHT) Overvalued in 2026?

Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued. The current stock price of $5.25 is trading 16.4% above its estimated GF Value™ of $4.51. GuruFocus considers Sight Sciences to be Modestly Overvalued.

Key valuation signals for SGHT:

  • GF Value Rank: 7 (75% above median its 10-year median of 4.00)
  • GF Value™: $4.51 vs. price of $5.25 (16.4% above fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sight Sciences Business Description

Address 4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
73GF Score

Get the complete analysis for SGHT

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.25
Price
$4.51
GF Value